BioCentury
ARTICLE | Clinical News

Avrobio falls on data for Fabry gene therapy

October 1, 2018 10:07 PM UTC

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase II trial.

The news sent the company’s shares tumbling $26.74 (52%) to $25.13 on Monday for a loss of over $640 million in market cap...

BCIQ Company Profiles

Avrobio Inc.

BCIQ Target Profiles

Alpha galactosidase A